Form 4: Vanda Pharmaceuticals Director Richard Dugan Awarded Over 59,000 Restricted Stock Units

Vanda Pharmaceuticals Inc. Director Richard W. Dugan was granted 59,225 restricted stock units (RSUs) on June 5, 2025, which are set to vest on June 5, 2026.

Summary

• Richard W. Dugan, a Director of Vanda Pharmaceuticals Inc. (VNDA), was granted 59,225 shares of common stock in the form of a time-based restricted stock unit (RSU) award.
• The transaction date for this acquisition was June 5, 2025, with the RSUs acquired at a price of $0 per share, which is typical for such grants.
• Following this transaction, Mr. Dugan's direct beneficial ownership of common stock increased to a total of 177,454 shares.
• 100% of the shares subject to this RSU award will vest on June 5, 2026, contingent upon Mr. Dugan's continuous service to the Issuer through that date.

Sentiment

Score: 6

Explanation: Slightly positive. While a routine compensation event, it signifies continued director involvement and aligns interests with shareholders, which is generally viewed favorably. The potential for minor dilution is offset by the positive governance implications.

Positives

• The grant of restricted stock units aligns the director's financial interests with those of shareholders, as the value of the award is directly tied to the company's stock performance.
• The one-year vesting schedule encourages long-term commitment and retention of the director's service to the company.
• An increase in beneficial ownership by a director can signal confidence in the company's future prospects and strategic direction.

Negatives

• The RSU grant represents potential future dilution for existing shareholders upon vesting, although this is a standard component of executive and director compensation.
• The award is time-based and does not appear to be tied to specific performance metrics, which some investors might prefer for executive incentives to ensure performance alignment.

Risks

• The actual realized value of the RSU award is subject to the future market price of Vanda Pharmaceuticals' common stock, meaning the value could be lower than the grant date value if the stock price declines.
• The RSUs are subject to forfeiture if the reporting person's continuous service to the Issuer ceases before the vesting date of June 5, 2026.

Future Outlook

The document primarily details an equity compensation grant and its vesting schedule, indicating a future alignment of the director's interests with the company's long-term performance through the vesting of restricted stock units on June 5, 2026.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries for publicly traded companies. It reflects standard practice for compensating directors with equity to align their interests with shareholders, a prevalent trend in corporate governance.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting of the RSUs, but also increased alignment of a director's interests with shareholder value.
• Employees: No direct impact mentioned for general employees.

Next Steps

• Vesting of the 59,225 Restricted Stock Units on June 5, 2026, provided continuous service is maintained.

Key Dates

Keywords

Vanda Pharmaceuticals, VNDA, SEC Form 4, Insider Transaction, Restricted Stock Unit, RSU, Director Compensation, Equity Award, Beneficial Ownership, Richard W. Dugan